T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ExxonMobil
XOM
|
+$1.76B |
| 2 |
Eli Lilly
LLY
|
+$1.4B |
| 3 |
Bank of America
BAC
|
+$1.3B |
| 4 |
Tesla
TSLA
|
+$1.19B |
| 5 |
Wells Fargo
WFC
|
+$784M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$6.47B |
| 2 |
Amazon
AMZN
|
+$3.71B |
| 3 |
Yum! Brands
YUM
|
+$2.84B |
| 4 |
Salesforce
CRM
|
+$2.77B |
| 5 |
Fortive
FTV
|
+$2.41B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.06% |
| 2 | Healthcare | 18.72% |
| 3 | Consumer Discretionary | 14.62% |
| 4 | Financials | 10.36% |
| 5 | Communication Services | 9.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BLUE
2576
DELISTED
bluebird bio
BLUE
| $179K | ﹤0.01% |
1,411
+351
| +33% | +$39.7K |
|
2577
On Holding
ONON
$10.6B
| $179K | ﹤0.01% |
11,092
-9,106,672
| -100% | -$182M |
|
2578
Kodak
KODK
$978M
| $177K | ﹤0.01% |
38,449
+3,494
| +10% | +$19.1K |
|
|
BNFT
2579
DELISTED
Benefitfocus, Inc.
BNFT
| $177K | ﹤0.01% |
27,795
+2,017
| +8% | +$15K |
|
2580
Acacia Research
ACTG
$449M
| $176K | ﹤0.01% |
43,500
+13,200
| +44% | +$60.9K |
|
2581
Cullinan Oncology
CGEM
$1.26B
| $175K | ﹤0.01% |
13,617
+1,871
| +16% | +$25.2K |
|
2582
Claros Mortgage Trust
CMTG
$268M
| $175K | ﹤0.01% |
+14,832
| New | +$255K |
|
2583
Goldgroup Mining Inc.
GORO
$211M
| $175K | ﹤0.01% |
105,908
-14,800
| -12% | -$25.1K |
|
|
TCS
2584
DELISTED
THE CONTAINER STORE GROUP, INC.
TCS
| $175K | ﹤0.01% |
2,371
+164
| +7% | +$16.5K |
|
|
SLGC
2585
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| $174K | ﹤0.01% |
59,904
-4,209,521
| -99% | -$17.7M |
|
2586
The Joint Corp
JYNT
$119M
| $172K | ﹤0.01% |
+10,920
| New | +$194K |
|
2587
CareCloud
CCLD
$104M
| $171K | ﹤0.01% |
40,800
| – | – |
|
2588
Gevo
GEVO
$401M
| $171K | ﹤0.01% |
74,753
+18,474
| +33% | +$51.5K |
|
2589
Phibro Animal Health
PAHC
$1.38B
| $171K | ﹤0.01% |
12,833
+1,239
| +11% | +$21.4K |
|
2590
SFL Corp
SFL
$1.61B
| $170K | ﹤0.01% |
18,572
+7,611
| +69% | +$77.1K |
|
|
TUP
2591
DELISTED
Tupperware Brands Corporation
TUP
| $169K | ﹤0.01% |
25,681
-10,183
| -28% | -$91.5K |
|
2592
DHT Holdings
DHT
$3.09B
| $167K | ﹤0.01% |
22,036
+8,575
| +64% | +$64.2K |
|
|
FSP
2593
Franklin Street Properties
FSP
$46.4M
| $167K | ﹤0.01% |
63,278
+5,942
| +10% | +$19.6K |
|
2594
First US Bancshares
FUSB
$90.7M
| $167K | ﹤0.01% |
20,950
| – | – |
|
|
NKLA
2595
DELISTED
Nikola Corporation Common Stock
NKLA
| $167K | ﹤0.01% |
1,581
+652
| +70% | +$110K |
|
2596
Spruce Power Holding Corp
SPRU
$33.6M
| $166K | ﹤0.01% |
23,263
+9,175
| +65% | +$87K |
|
2597
Hillman Solutions
HLMN
$1.71B
| $165K | ﹤0.01% |
21,812
+8,969
| +70% | +$79K |
|
|
VXRT
2598
DELISTED
Vaxart
VXRT
| $165K | ﹤0.01% |
75,304
-88,114
| -54% | -$304K |
|
|
VBIV
2599
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $165K | ﹤0.01% |
7,710
+1,466
| +23% | +$39.5K |
|
2600
Phathom Pharmaceuticals
PHAT
$743M
| $163K | ﹤0.01% |
14,635
+4,295
| +42% | +$40.9K |
|
Similar funds
T. Rowe Price Associates's Q3 2022 Portfolio in Review
As of Q3 2022, T. Rowe Price Associates held 3,114 positions worth $610B, down 23% from $791B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
T. Rowe Price Associates withdrew a net $168B in Q3 2022, closing 171 positions and reducing 1,248 holdings. Its most notable exit was Alcon, an estimated $1.51B position sold in full.
By sector, the portfolio is most concentrated in Technology at 26% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, T. Rowe Price Associates opened a new position in Corebridge Financial worth $194M.
- T. Rowe Price Associates's largest Q3 2022 buy was Corebridge Financial: 9,831,688 shares worth $194M.
- T. Rowe Price Associates added most to ExxonMobil in Q3 2022, an estimated $1.76B increase.
- T. Rowe Price Associates's biggest Q3 2022 reduction was Microsoft, cutting an estimated $6.47B.
- T. Rowe Price Associates fully exited Alcon in Q3 2022, selling an estimated $1.51B.
- T. Rowe Price Associates's ten largest holdings make up 31% of its $610B portfolio in Q3 2022.
- T. Rowe Price Associates opened 154 new positions and closed 171 in Q3 2022.
- T. Rowe Price Associates's portfolio value fell 23% quarter-over-quarter to $610B.
Based on T. Rowe Price Associates's 13F filing for Q3 2022, filed 14 Nov 2022.